In­tro­duc­ing End­points Stu­dio, a new way to ad­ver­tise with End­points-craft­ed brand­ing cam­paigns

Since our start in 2016, End­points News has grown fast while ex­e­cut­ing our mis­sion to cov­er bio­phar­ma’s most crit­i­cal de­vel­op­ments for in­dus­try pros world­wide. As read­er­ship has grown, our ad­ver­tis­ing busi­ness has too. End­points ad­ver­tis­ing part­ners sup­port the mis­sion and en­gage their de­sired au­di­ences through an­nounce­ments on our email and web plat­forms, brand recog­ni­tion in our event cov­er­age and spon­sor­ships of End­points dai­ly and week­ly re­ports.

And to­day, we’re launch­ing our newest evo­lu­tion of the busi­ness: End­points Stu­dio.

Now, life sci­ences mar­keters can pro­duce brand­ed con­tent in the cal­iber read­ers ex­pect from End­points. Led by Kari Abit­bol, our new head of ad­ver­tis­ing and mar­ket­ing pro­grams, the End­points Stu­dio team de­vel­ops mea­sur­able cam­paigns in­formed with our first-par­ty da­ta.

Our line­up fea­tures the Stu­dio FSP and Stu­dio FSP+, an en­hance­ment of our long-es­tab­lished spon­sored posts with ar­ti­cles au­thored by our Stu­dio team — with an op­por­tu­ni­ty to do lead-cap­ture. Stu­dio FSP and FSP+ ben­e­fit from the same, ex­clu­sive pro­mo­tion across our email re­ports, home­page and news streams. We’re al­so in­tro­duc­ing Stu­dio we­bi­na­rs, which run like cus­tom and ed­i­to­r­i­al we­bi­na­rs but are pro­grammed ex­clu­sive­ly by our Stu­dio team, and E-blast+, which in­cludes an End­points-cre­at­ed and host­ed land­ing page de­signed for high con­ver­sion.

So what makes End­points Stu­dio dif­fer­ent, ex­act­ly? Check out the new stu­dio web­site to learn more about our prod­ucts, top­ics (which span cell and gene ther­a­py to phar­ma mar­ket­ing) and how we use our own da­ta to de­liv­er bet­ter con­tent for our read­ers and stronger re­sults for our ad­ver­tis­ers. And soon, you’ll see case stud­ies about how we’re learn­ing from our own Stu­dio pro­grams to gen­er­ate even greater im­pact.

In 2021, our com­mit­ment was to go broad­er and deep­er. We launched four week­ly re­ports — End­points Man­u­fac­tur­ing, End­points Week­ly, End­points FDA+ and the new­ly re­leased End­points Mar­ket­ingRx — and de­liv­ered break­ing news that fu­eled a wave of new sub­scribers. Our ac­tive email dai­ly read­er­ship is near­ing 125,000 sub­scribers as we close out the year. We’ve grown our team from 22 full-time staff in Jan­u­ary to 35 full-time em­ploy­ees (and count­ing) to ma­ture and sup­port these ini­tia­tives at scale.

As we look to the year ahead, we’re great­ly thank­ful for the con­tin­ued sup­port from read­ers, sub­scribers and spon­sors that has cat­a­pult­ed us from a small me­dia com­pa­ny in­to a thriv­ing force whose work is seen dai­ly by lead­er­ship at the top 25 phar­ma com­pa­nies and thou­sands of biotech star­tups across the globe. And we’re just get­ting start­ed.

Stay tuned for more End­points Stu­dio up­dates from Kari next year, and reach out to Chief Rev­enue Of­fi­cer Mike Peck (mike@end­pointsnews.com) with Stu­dio sched­ul­ing and pric­ing re­quests.

Graphic: Alexander Lefterov for Endpoints News

Small biotechs with big drug am­bi­tions threat­en to up­end the tra­di­tion­al drug launch play­book

Of the countless decisions Vlad Coric had to make as Biohaven’s CEO over the past seven years, there was one that felt particularly nerve-wracking: Instead of selling to a Big Pharma, the company decided it would commercialize its migraine drug itself.

“I remember some investors yelling and pounding on the table like, you can’t do this. What are you thinking? You’re going to get crushed by AbbVie,” he recalled.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Mar­ket­ingRx roundup: Pfiz­er de­buts Pre­vnar 20 TV ads; Lil­ly gets first FDA 2022 pro­mo slap down let­ter

Pfizer debuted its first TV ad for its Prevnar 20 next-generation pneumococcal pneumonia vaccine. In the 60-second spot, several people (actor portrayals) with their ages listed as 65 or older are shown walking into a clinic as they turn to say they’re getting vaccinated with Prevnar 20 because they’re at risk.

The update to Pfizer’s blockbuster Prevnar 13 vaccine was approved in June, and as its name suggests is a vaccine for 20 serotypes — the original 13 plus seven more that cause pneumococcal disease. Pfizer used to spend heavily on TV ads to promote Prevnar 13 in 2018 and 2019 but cut back its TV budgets in the past two fall and winter seasonal spending cycles. Prevnar had been Pfizer’s top-selling drug, notching sales of just under $6 billion in 2020, and was the world’s top-selling vaccine before the Covid-19 vaccines came to market last year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Albert Bourla (Photo by Steven Ferdman/Getty Images)

UP­DAT­ED: Pfiz­er fields a CRL for a $295M rare dis­ease play, giv­ing ri­val a big head start

Pfizer won’t be adding a new rare disease drug to the franchise club — for now, anyway.

The pharma giant put out word that their FDA application for the growth hormone therapy somatrogon got the regulatory heave-ho, though they didn’t even hint at a reason for the CRL. Following standard operating procedure, Pfizer said in a terse missive that they would be working with regulators on a followup.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Alexander Lefterov/Endpoints News

A new can­cer im­munother­a­py brings cau­tious hope for a field long await­ing the next big break­through

Bob Seibert sat silent across from his daughter at their favorite Spanish restaurant near his home in Charleston County, SC, their paella growing cold as he read through all the places in his body doctors found tumors.

He had texted his wife, a pediatric intensive care nurse, when he got the alert that his online chart was ready. Although he saw immediately it was bad, many of the terms — peritoneal, right iliac — were inscrutable. But she was five hours downstate, at a loud group dinner the night before another daughter’s cheer competition.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Florida Gov. Ron DeSantis (AP Photo/Wilfredo Lee, File)

Opin­ion: Flori­da is so mAb crazy, Ron De­San­tis wants to use mAbs that don't work

Florida Gov. Ron DeSantis is trying so hard to politicize the FDA and demonize the federal government that he entered into an alternate universe on Monday evening in describing a recent FDA action to restrict the use of two monoclonal antibody, or mAb, treatments for Covid-19 that don’t work against Omicron.

Without further ado, let’s break down his statement from last night, line by line, adjective by adjective.

Not cheap­er by the dozen: Bris­tol My­ers be­comes the 12th phar­ma com­pa­ny to re­strict 340B sales

Bristol Myers Squibb recently joined 11 of its peer pharma companies in limiting how many contract pharmacies can access certain drugs discounted by a federal program known as 340B.

Bristol Myers is just the latest in a series of high-profile pharma companies moving in their own direction as the Biden administration’s Health Resources and Services Administration struggles to rein in the drug discount program for the neediest Americans.

Joaquin Duato, J&J CEO (Photo by Charles Sykes/Invision/AP)

New J&J CEO Joaquin Du­a­to promis­es an ag­gres­sive M&A hunt in quest to grow phar­ma sales

Joaquin Duato stepped away from the sideline and directly into the spotlight on Tuesday, delivering his first quarterly review for J&J as its newly-tapped CEO after an 11-year run in senior posts. And he had some mixed financial news to deliver today while laying claim to a string of blockbuster drugs in the making and outlining an appetite for small and medium-sized M&A deals.

Duato also didn’t exactly shun large buyouts when asked about the future of the company’s medtech business — where they look to be in either the top or number 2 position in every segment they’re in — even though the bar for getting those deals done is so much higher.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Amgen's Twitter campaign #DearAsthma inspired thousands of people to express struggles and frustrations with the disease

Am­gen’s #Dear­Asth­ma spon­sored tweet lands big on game day, spark­ing thou­sands to re­spond

Amgen wanted to know how people with asthma really felt about daily life with the disease. So it bought a promoted tweet on Twitter noting the not-so-simple realities of life with asthma and ended the post with a #DearAsthma hashtag, a megaphone emoji and a re-tweet button.

That was just over one week ago and the responses haven’t stopped. More than 7,000 posts so far on Twitter replied to #DearAsthma to detail struggles of daily life, expressing humor, frustration and sometimes anger. More than a few f-bombs have been typed or gif-ed in reply to communicate just how much many people “hate” the disease.

Pfiz­er, Bris­tol My­ers dom­i­nate top 10 pre­dic­tions for the best-sell­ing drugs of 2022

The annual exercise where analysts try and predict which drugs will become blockbusters and make the most money tends to highlight the biggest trends in biopharma R&D. 2022 is no exception.

The team at Evaluate Vantage published its predictions for the top 10 selling drugs for the year — expecting tens of billions of dollars in sales and highlighting an industry-wide focus on certain diseases and indications.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.